pharmaphorum

OCTOBER 13, 2022

GSK’s vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme. The two vaccines are heading for regulatory filings shortly, with approvals due around the same time in 2023.

Prospecting 80

Prospecting Marketing Competition Safety 80

European Pharmaceutical Review

JULY 20, 2023

In June 2023, an array of leading voices in AAV development for cell and gene therapies articulated the current challenges and their optimism for the rapidly advancing sector at the Cell and Gene Therapy Summit event in London. More recently, the FDA granted approval of Roctavian in June 2023.

Consulting 54

Consulting Side effects Manufacturing Safety 54

Medico Reach

FEBRUARY 8, 2023

The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. Are you intrigued to know what technologies will rule the pharma market and how they can benefit your business in 2023? I anticipate this trend will only continue in 2023.” from 2023 to 2030. Let’s find out!

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. Eight companies floated in the third quarter of 2023, raising $1.3 Many of those companies that were able to squeeze through the narrow IPO window have struggled.

Biopharma 111

Biopharma Pharma Marketing Management 111

European Pharmaceutical Review

MAY 2, 2023

However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. By collaborating with several stakeholders and authorities, multiple stages of development can take place concurrently to speed up R&D without compromising safety protocols.

Patients 94

Patients Medicine Marketing Medical 94

pharmaphorum

NOVEMBER 16, 2022

Bleak prospects, indeed. The specifics of an exciting prospect. So, really,” he continued, “[there are] three major take-homes to talk about: first efficacy, then function, and then safety. It’s one of the most common causes of blindness across Europe and across the United States, and many developed countries around the world.

Safety 93

Safety Patients Consulting Prospecting 93

European Pharmaceutical Review

JUNE 27, 2023

difficile in December 2022, the microbiome therapies space in 2023 has continued to see revolutionary developments and continued research advancement. Notably, gut microbiome was found to linked to cancer CAR T therapy response, based data from the largest prospective study of its kind, published in Nature Medicine in March 2023.

Food and Drug Administration 92

Food and Drug Administration Manufacturing Medicine Pharma 92

Legacy MEDSearch

JUNE 16, 2023

The prospective, randomized clinical trial is designed to evaluate the safety and effectiveness of the pro disc C Vivo and pro disc C SK system by comparing it with an approved TDR product as a control for 2-level indications, making it the first and only of its kind with two investigational devices and a TDR control.

Food and Drug Administration 52

Food and Drug Administration Recruitment Safety Medical 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. While data from the first two cohorts did not show any HIV insert-specific T cell response , a third cohort readout is expected in H1 2023.

Medicine 117

Medicine Prospecting Safety Manufacturing 117

European Pharmaceutical Review

OCTOBER 12, 2023

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. With order books having been below their long-run average for eight out of the last nine months, manufacturers see little prospect of a recovery in the final months of the year.

Pharmaceutical manufacturing 79

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 79

Spotio

AUGUST 8, 2023

Keep reading to learn what solar design software is, the top 12 options available in 2023, the numerous benefits associated with this type of solution and more. 12 Best Solar Design Software Tools in 2023 So, what is the best solar design software for your company? That’s what we’ll uncover in this article.

Sales 52

Sales Engineering Prospecting Marketing 52

Clarify Health

MARCH 1, 2023

As one of the largest trials ever conducted testing the impact of nudges on opioid prescribing, this study demonstrated the potential for health systems to change clinicians’ behavior and improve patient safety by using scalable nudge interventions.[5] You can learn more about Clarify’s speaking sessions at HIMSS23 at [link].

Physicians 52

Physicians Prescription Medicine Healthcare 52

Spotio

JULY 5, 2023

Obvious value propositions include: “safety” and “peace of mind.” Because stories help sales reps like yourself build personal connections with their prospects. Once these personal connections are built, your prospects will trust you more. Ask your prospect a question to help engage them in conversation.

Sales 40

Sales Prospecting Sales pitches Education 40

Legacy MEDSearch

MAY 1, 2023

the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB. BlueWind Medical, Ltd., of patients compliant with once daily treatments at 12 months.

Patients 52

Patients Medical Safety Recruitment 52

pharmaphorum

SEPTEMBER 30, 2022

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy (DMD), as it aims for a launch in the middle of 2023. It is going for early approval based on the totality of the clinical data.

FDA 93

FDA Prospecting Patients Safety 93

Legacy MEDSearch

APRIL 21, 2023

.” Premarket approval was granted based on clinical evaluation of Lava LES in a prospective, multicenter, single-arm study (the “LAVA study” ) evaluating safety and efficacy in acute peripheral arterial hemorrhages.

FDA 52

FDA Safety Recruitment Prospecting 52

Integrity Solutions

JANUARY 23, 2023

“Be more metrics-driven in 2023 to better clarify where individual salespeople should be investing their time, energy, resources and priorities to maximize individual and team results,” Wedderburn advises. Bruce Wedderburn has previously written about the importance of determining the right sales training metrics.

Sales 78

Sales Training Sales Management Management 78

Legacy MEDSearch

MAY 11, 2023

(PMT), a leader in medical device innovation for spine surgery, today announced the close of enrollment in its FUSE Study — a prospective, multicenter, randomized, Investigational Device Exemption (IDE) clinical study evaluating the safety and effectiveness of its Posterior Cervical Stabilization System (PCSS) in 3-level cervical fusion patients.

Medical 52

Medical Patients Recruitment Management 52

Nixon Gwilt Law

NOVEMBER 5, 2021

Extension in Coverage for Category 3 Telehealth Services CMS finalized the proposed extended timeframe for reimbursement of temporary, Category 3 telehealth services until the end of 2023. CMS will evaluate such requests and propose any additions in the 2023 Proposed Medicare Physician Fee Schedule.

Physicians 52

Physicians Professional Services Side effects Medical 52

Pharmaceutical Technology

JUNE 6, 2023

Ellipses reported preliminary efficacy and safety data for the 109 patients enrolled in the trial. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Pharma 52

Pharma Patients Prospecting Competition 52

Salesforce

APRIL 7, 2021

The four critical uncertainties we proposed are also still useful for tracking the potential outcomes, but many new developments have changed the upside and downside prospects, both for the world as a whole and across regions. While difficult to scale, that keeps the prospect of herd immunity within reach. Citizens across the U.S.,

Prospecting 52

Prospecting Management Government Marketing 52

Pharmaceutical Technology

APRIL 20, 2023

Following a tumultuous development cycle, DBV Technologies will now have to conduct an additional safety study of its peanut allergy Viaskin patch in toddlers ages 1–3 years, based on written correspondence from the US Food and Drug Administration (FDA). In March 2023, the company announced the screening of the trial’s first patient.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Prospecting 52

Pharmaceutical Technology

JANUARY 22, 2023

More therapies to meet unmet needs GlobalData predicts that at least 35 US regulatory decisions on drugs for rare diseases are on the horizon for 2023. In 2023, Sarepta Therapeutics has a PDUFA date for the first gene transfer DMD therapy, delandistrogene moxeparvovec (SRP 9001), on May 29. In clinical trials, the drug showed a 3.8-point

FDA 126

FDA Safety Pharmaceutical Patients 126

Pharmaceutical Technology

MAY 4, 2023

The approval comes after an FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted in support of Arexvy’s effectiveness and safety. Furthermore, in April 2023, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion in support of the vaccine’s approval.

FDA 64

FDA Safety Medicine Prescription 64

Pharmaceutical Technology

FEBRUARY 6, 2023

In the midst of tough predictions for 2023 due to inflation and a difficult funding environment, Pliant Therapeutics closed an oversubscribed $287.5 Leading up to 2023, experts have said a company’s financial wellbeing may depend on its economic position when the market shifted. The company plans to release the final data in Q2 2023.

Marketing 59

Marketing Pharmaceutical FDA Prospecting 59

Pharmaceutical Technology

MAY 23, 2023

In its Q1 report , Centessa stated plans to present more data from part five of the open-label expansion of the Phase IIa study, subject to completion, at an undisclosed scientific meeting in 2023. Haemophilia B is a clotting disorder caused by a coagulation factor IX deficiency. Free Report How is the Biopharmaceutical industry evolving?

FDA 59

FDA Food and Drug Administration Prospecting Food 59

Pharmaceutical Technology

MARCH 23, 2023

Spruce is currently studying the safety and efficacy of tildacerfont in a Phase II study (NCT05370521) in participants ages 18–40 years with PCOS and elevated adrenal androgens. The study’s results are anticipated for release in mid-2023. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry.

Medical 52

Medical Management Patients Transportation 52

Pharmaceutical Technology

MAY 1, 2023

After a US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) Advisory Committee (AdCom) meeting in March 2023 voted unanimously in support of GSK’s respiratory syncytial virus vaccine, the odds for an approval have increased. Even in LICs, they do yearly checks or catch up campaigns.

Food and Drug Administration 52

Food and Drug Administration Medicine Pharmaceutical Marketing 52

Pharmaceutical Technology

JUNE 22, 2023

There, the European Commissioner for Health and Food Safety, Stella Kyriakides, stated that incentives need to be used to fuel innovation needed to bring new antimicrobials to the market. Årdal previously wrote about the voucher scheme in a February 2023 article published in The Lancet.

Pharma 52

Pharma Pharmaceutical Government Marketing 52

Pharmaceutical Technology

JUNE 5, 2023

The treatment had an acceptable safety profile in combination with chemotherapy. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. They experienced PFS of 7.1 months, and median OS of 15.6

Side effects 52

Side effects Patients Leads Prospecting 52

Pharmaceutical Technology

MAY 25, 2023

According to the companies report, the BT-001 single agent treatment was completed in 18 patients and no safety concerns were reported. The independent Safety Review Committee has now approved initiation of the combination part of the trial with pembrolizumab. The BI-1206 is also under Phase I/IIa of development ( NCT04219254 ).

Safety 52

Safety Patients Prospecting Competition 52